Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Gilead Sciences, Inc. : FDA Panel Backs Gilead's HIV 'Quad' Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/11/2012 | 09:06pm CET
   By Jennifer Corbett Dooren 
   Of  
 

A federal advisory panel Friday backed an experimental Gilead Sciences Inc. (GILD) HIV medicine known as the Quad.

The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.

The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.

Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.

Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES, INC.
12/01 GILEAD SCIENCES, INC. (NASDAQ : GILD) Begins A Process That Could Alleviate Its ..
11/29 GILEAD SCIENCES, INC. (NASDAQ : GILD) Takes Lead Against AbbVie Inc (NYSE:ABBV) ..
11/28 Global Hepatitis C Drug Market - Merck & Co, Kenilworth, Roche, Basel GlaxoSm..
11/23 MATINAS BIOPHARMA HOLDINGS INC. (OTC : MTNB) Can Take A $350M Antifungal Market ..
11/23 GILEAD SCIENCES : Canada, Inc., is awarded prestigious Prix Galien Canada Innova..
11/22 GILEAD SCIENCES : Announces Top-Line Results From Two Phase 3 Studies Evaluating..
11/22 GILEAD SCIENCES : Announces Promotion of James R. Meyers to Executive Vice Presi..
11/22 GILEAD SCIENCES : to Present at the Annual Piper Jaffray Healthcare Conference o..
11/22 GILEAD SCIENCES : European CHMP Adopts Positive Opinion for Gilead's Vemlidy® Te..
11/17 GILEAD SCIENCES : Patent Issued for Solid Forms of Tenofovir (USPTO 9487546)
More news
Sector news : Bio Therapeutic Drugs
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
12/02 TRUMP AS REAGAN 2.0 - THE ANALOGY IS : What's Next
12/02 GILEAD : M&A Coming Soon
12/02 Gilead Has 1 More Trick Up Its Sleeve
12/02 STOCK EXCHANGE : Model Picks Teach Us To Manage Risk
12/01 With 2016 Nearing A Close, Our Dividend Growth Portfolio Is Up Almost 10%
Advertisement
Financials ($)
Sales 2016 30 175 M
EBIT 2016 20 022 M
Net income 2016 13 955 M
Debt 2016 1 855 M
Yield 2016 2,56%
P/E ratio 2016 6,96
P/E ratio 2017 6,94
EV / Sales 2016 3,22x
EV / Sales 2017 3,35x
Capitalization 95 410 M
More Financials
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Full-screen chart
Technical analysis trends GILEAD SCIENCES, ...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 97,4 $
Spread / Average Target 35%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-27.17%95 410
AMGEN, INC.-11.25%107 132
CELGENE CORPORATION-1.78%91 187
REGENERON PHARMACEUTIC..-31.34%39 310
ACTELION LTD40.40%21 739
VERTEX PHARMACEUTICALS..-35.14%18 727
More Results